Critical Roles of N6-Methyladenosine (m6A) in Cancer and Virus Infection
- PMID: 32709063
- PMCID: PMC7408378
- DOI: 10.3390/biom10071071
Critical Roles of N6-Methyladenosine (m6A) in Cancer and Virus Infection
Abstract
Studies have shown that epigenetic abnormalities are involved in various diseases, including cancer. In particular, in order to realize precision medicine, the integrated analysis of genetics and epigenetics is considered to be important; detailed epigenetic analysis in the medical field has been becoming increasingly important. In the epigenetics analysis, DNA methylation and histone modification analyses have been actively studied for a long time, and many important findings were accumulated. On the other hand, recently, attention has also been focused on RNA modification in the field of epigenetics; now it is known that RNA modification is associated with various biological functions, such as regulation of gene expression. Among RNA modifications, functional analysis of N6-methyladenosine (m6A), the most abundant RNA modification found from humans to plants is actively progressing, and it has also been known that m6A abnormality is involved in cancer and other diseases. Importantly, recent studies have shown that m6A is related to viral infections. Considering the current world situation under threat of viral infections, it is important to deepen knowledge of RNA modification from the viewpoint of viral diseases. Hence, in this review, we have summarized the recent findings regarding the roles of RNA modifications in biological functions, cancer biology, and virus infection, particularly focusing on m6A in mRNA.
Keywords: RNA modification; RNA virus; cancer; epigenetics; methylation.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures



Similar articles
-
m6A-binding proteins: the emerging crucial performers in epigenetics.J Hematol Oncol. 2020 Apr 10;13(1):35. doi: 10.1186/s13045-020-00872-8. J Hematol Oncol. 2020. PMID: 32276589 Free PMC article. Review.
-
A dynamic reversible RNA N6 -methyladenosine modification: current status and perspectives.J Cell Physiol. 2019 Jun;234(6):7948-7956. doi: 10.1002/jcp.28014. Epub 2019 Jan 15. J Cell Physiol. 2019. PMID: 30644095 Review.
-
New sights in cancer: Component and function of N6-methyladenosine modification.Biomed Pharmacother. 2020 Feb;122:109694. doi: 10.1016/j.biopha.2019.109694. Epub 2019 Dec 30. Biomed Pharmacother. 2020. PMID: 31918269 Review.
-
RNA Modifications and Epigenetics in Modulation of Lung Cancer and Pulmonary Diseases.Int J Mol Sci. 2021 Sep 30;22(19):10592. doi: 10.3390/ijms221910592. Int J Mol Sci. 2021. PMID: 34638933 Free PMC article. Review.
-
From A to m6A: The Emerging Viral Epitranscriptome.Viruses. 2021 Jun 1;13(6):1049. doi: 10.3390/v13061049. Viruses. 2021. PMID: 34205979 Free PMC article. Review.
Cited by
-
Regulation of m6A Methylation as a New Therapeutic Option against COVID-19.Pharmaceuticals (Basel). 2021 Nov 8;14(11):1135. doi: 10.3390/ph14111135. Pharmaceuticals (Basel). 2021. PMID: 34832917 Free PMC article.
-
Comprehensive profiling analysis of the N6-methyladenosine-modified circular RNA transcriptome in cultured cells infected with Marek's disease virus.Sci Rep. 2021 May 26;11(1):11084. doi: 10.1038/s41598-021-90548-1. Sci Rep. 2021. PMID: 34040106 Free PMC article.
-
Downregulation of METTL6 mitigates cell progression, migration, invasion and adhesion in hepatocellular carcinoma by inhibiting cell adhesion molecules.Int J Oncol. 2022 Jan;60(1):4. doi: 10.3892/ijo.2021.5294. Epub 2021 Dec 16. Int J Oncol. 2022. PMID: 34913069 Free PMC article.
-
Application of Artificial Intelligence Technology in Oncology: Towards the Establishment of Precision Medicine.Cancers (Basel). 2020 Nov 26;12(12):3532. doi: 10.3390/cancers12123532. Cancers (Basel). 2020. PMID: 33256107 Free PMC article. Review.
-
RNA m6A methylation regulators in liver cancer.Cancer Cell Int. 2024 Jan 2;24(1):1. doi: 10.1186/s12935-023-03197-x. Cancer Cell Int. 2024. PMID: 38166832 Free PMC article. Review.
References
-
- Ji P., Diederichs S., Wang W., Boing S., Metzger R., Schneider P.M., Tidow N., Brandt B., Buerger H., Bulk E., et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22:8031–8041. doi: 10.1038/sj.onc.1206928. - DOI - PubMed
-
- Hebert S.S., Horre K., Nicolai L., Papadopoulou A.S., Mandemakers W., Silahtaroglu A.N., Kauppinen S., Delacourte A., De Strooper B. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta-secretase expression. Proc. Natl. Acad. Sci. USA. 2008;105:6415–6420. doi: 10.1073/pnas.0710263105. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical